Definium Therapeutics (DFTX) Gains from Investment Securities (2023 - 2026)

Definium Therapeutics (DFTX) has 4 years of Gains from Investment Securities data on file, last reported at $20.0 million in Q1 2026.

• On a quarterly basis, Gains from Investment Securities rose 386.41% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $49.9 million, a 308.24% increase from a year earlier, with the FY2025 full-year figure at $22.8 million, up 43.22% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $20.0 million, up from $5.1 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for DFTX reached as high as $32.9 million in Q1 2024 and fell as low as -$13.4 million in Q2 2024.
• Historically, Gains from Investment Securities has averaged $5.0 million across 4 years, with a median of $3.0 million in 2023.
• On a YoY basis, Gains from Investment Securities climbed as much as 534.39% in 2024 and fell as far as 993.95% in 2024.
• Year by year, Gains from Investment Securities stood at $3.0 million in 2023, then soared by 63.68% to $4.9 million in 2024, then grew by 4.2% to $5.1 million in 2025, then soared by 296.4% to $20.0 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were $20.0 million in Q1 2026, $5.1 million in Q4 2025, and $22.5 million in Q3 2025.